Trial ID or NCT#
FLIP topography has been FDA cleared to evaluate a variety of esophageal conditions, but has never been evaluated in patients with scleroderma. The investigators hope to evaluate this technology in patients who have scleroderma and various esophageal symptoms, and compare to non-scleroderma patients.
Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma
Contact us to find out if this trial is right for you.
John O Clarke, MD